Activated PPARd Protects from Senescence Figure 1. L-165041 prevents doxorubicin-induced changes in neonatal rat cardiomyocytes. Incubation for 3 h with low dose doxorubicin 0.1 mM (Dox 0.1) modifies the expression levels of telomere binding factor 2 (TRF2), the cell cycle and cell viability. Pre-treatment for 2 h with L- 165041 (L-165) prevents doxorubicin-induced modifications. (A) TRF2 mRNA evaluated 4 h after doxorubicin treatment. *p,0.05 versus control (ct), 1p,0.05 versus Dox 0.1. (B) FACS analysis of cell cycle distribution 24 h after treatment with Dox 0.1. Filled line: untreated cells; red line: cells treated with Table. Dox (C) 0.1; Cell green viability line: determined cells pre-treated by MTT with Assay.ˆp,0.05 L-165041 and versus then day treated 0. {p,0.05 with Dox versus 0.1. day Percentages 1. N p,0.05 of cell versus subpopulations day 2. # p,0.05 are summarized versus day in 3. the doi:10.1371/journal.pone.0046126.g001 PLOS ONE | www.plosone.org 3 September 2012 | Volume 7 | Issue 9 | e46126